Egalet announced that the Food and Drug Administration (FDA) has tentatively approved an update to the Arymo ER (morphine sulfate) extended-release tablets labeling to include data from a Category 2/3 intranasal human abuse potential (HAP) study and an intranasal abuse-deterrent claim. 

The single-center, randomized, double-blind, double-dummy, active- and placebo-controlled, 5 period crossover study (N=46) evaluated the abuse potential of Arymo ER vs MS Contin in non-dependent, recreational opioid users when given intranasally. The primary endpoint was achieved, showing that after insufflation, manipualted Arymo ER resulted in significantly less (P<0.0001) drug liking vs crushed MS Contin. 

Moreover, the data showed patients given manipulated Arymo ER intranasally had a significantly reduced likelihood of taking the drug again (P<0.0001) vs crushed MS Contin. This data was not included in the original New Drug Application (NDA) label at time of approval due to exclusivity granted to another company. The final approval is anticipated when the exclusivity period ends on October 2, 2018. 

Related Articles

Arymo ER, a CII controlled substance, is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The Company’s Guardian Technology allows for the development of tablets that are difficult to manipulate for misuse and abuse. Clinical data have shown a greater resistance to cutting, crushing, grinding or breaking when compared to non-abuse-deterrent morphine sulfate extended-release tablets; abuse via injection is also expected to be difficult based on its physical and chemical properties.

Continue Reading

Arymo ER is available as 15mg, 30mg, and 60mg strength extended-release tablets in 100-count bottles

For more information call (610) 833-4200 or visit